Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy

Kim, Jong Gwang; Ryoo, Baek Yeol; Park, Yeon Hee; Kim, Bong Seog; Kim, Taeyou; Im, Young Hyuck; Kang, Yoon Koo

doi:10.1007/s00280-007-0476-x

Cited by 90 publications

(82 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taking such a high RR into account, one may assume that the results in terms of TTP (199 days) and MST (367 days) are not impressive. However, considering that this study included 11 patients with distant metastases to liver, peritoneum and bone, which are reportedly poor prognostic factors (Chau et al, 2004;Kim et al, 2007), the present results of TTP and MST are, we believe, reasonably acceptable. An important finding in this study was that there were no cases of PD, unlike in other previous studies.…”

Section: Discussionmentioning

confidence: 57%

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer

et al. 2007

View full text Add to dashboard Cite

The aim of this dose escalation study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs) and preliminary efficacy of docetaxel, S-1 and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Seventeen patients received oral S-1 (40 mg m À2 bid) on days 1 -14, intravenous cisplatin (60 mg m À2 ) and docetaxel (60, 70 or 80 mg m À2 depending on DLT) on day 8 every 3 weeks. The MTD of this combination was presumed to be docetaxel 70 mg m À2 . At this dose level, 40% of the patients (two of five) developed grade 4 neutropenia and 20% (one of five) exhibited grade 3 nausea during the first course. Therefore, the recommended dose of docetaxel was defined as 60 mg m À2 . The DLT was neutropenia. The response rate (RR) was 88.2% (15 of 17), consisting of one complete response and 14 partial responses. There were two stable diseases but no progressive disease. Of these 15 responders, four (23.5%) with high VEGF expression showed rapid tumour regression and achieved downstaging, leading to subsequent curative gastrectomy. Three of these have been disease free for about 3 years, suggesting a complete cure. In conclusion, this regimen was tolerable and showed a quite high RR, with an appreciable downstaging rate in metastatic gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 57%

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Our present data were assessed by using technetium bone scintigraphy and were evaluated with other methods. Besides CT or MRI, gallium-67 uptake bone scintigraphy can be useful to differentiate inflammatory bone lesions from bone metastasis [30].…”

Section: Discussionmentioning

confidence: 99%

Bone recurrence after curative resection of gastric cancer

Park

Song

et al. 2012

Gastric Cancer

View full text Add to dashboard Cite

Background Standard follow up for bone recurrence has not yet been established for gastric cancer after surgical resection. The aim of this study was to investigate the incidence of and related risk factors for bone recurrence after surgical resection of gastric cancer. Methods A cohort of 3035 gastric cancer patients after curative resection was reviewed. We analyzed the patients who had bone scintigraphy before the surgery as well as during the follow-up period. The incidence of and the risk factors for bone recurrence after surgical resection of gastric cancer were investigated. Results In a total of 1683 patients analyzed, bone recurrence was detected in 30 patients (1.8 %). The incidence of bone recurrence was significantly higher in advanced gastric cancers than in early lesions (3.5 vs. 0.4 %, p \ 0.01). The most common recurrence site was the spine, followed by pelvic bone and rib. Most patients had multiple bone metastases. The median time for recurrence was 28 months (range 4-111) from the surgery. In univariate analysis, the recurrence rate was higher in the tumors with large size, undifferentiated pathology, location in the body, and advanced stage. In multivariate analysis, lymph node metastasis (N2/N3 vs. N0/N0I) was the most predictable risk factor for bone recurrence [hazard ratio [HR] 1.44 (95% confidence interval [CI] 1.217-1.694)] and depth of invasion (T2-4 vs. T1) was also independently associated with bone recurrence. Conclusions The incidence of bone recurrence was low after curative surgery in patients with gastric cancer. Intensive follow up with bone scintigraphy seems to be unnecessary in these patients.

show abstract

“…Several reports have suggested that the presence of peritoneal metastasis or ascites is associated with poor survival in patients with AGC [8][9][10][11]. To improve the prognosis for patients with AGC and peritoneal metastasis, several clinical trials have been conducted [12][13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis

et al. 2012

View full text Add to dashboard Cite

Background There are few data on the efficacy of combination chemotherapy with a fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer (AGC) complicated by peritoneal metastasis, especially massive ascites. Methods We retrospectively evaluated the efficacy and safety of a fluoropyrimidine (S-1 or capecitabine) plus cisplatin as first-line chemotherapy in 120 patients with AGC and peritoneal metastasis. Results Ascites was detected in 50 patients, with 11 patients having massive ascites. Median progression-free survival (PFS) and overall survival (OS) of all patients was 6.1 and 15.9 months, respectively. The PFS and OS were shorter in patients with massive ascites (n = 11; 3.7 and 9.5 months) compared with patients with small or moderate ascites (n = 39; 5.8 and 13.5 months) or patients without ascites (n = 70; 6.9 and 18.1 months). The objective response in terms of ascites was similar whether ascites was massive (4 of 11 patients; 36.4%) or small or moderate (16 of 39 patients; 41%). The frequencies of grade 3 or higher toxicity or treatment discontinuation due to toxicity are relatively similar across ascites groups. Conclusions Fluoropyrimidine plus cisplatin appears to be tolerated in selected patients with peritoneal metastasis.

show abstract

Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy

Cited by 90 publications

References 26 publications

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer

Bone recurrence after curative resection of gastric cancer

Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis

Contact Info

Product

Resources

About